biomark system Search Results


electrodes  (KCAS Bioanalytical and Biomarker Services)
94
KCAS Bioanalytical and Biomarker Services electrodes
Electrodes, supplied by KCAS Bioanalytical and Biomarker Services, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/electrodes/product/KCAS Bioanalytical and Biomarker Services
Average 94 stars, based on 1 article reviews
electrodes - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
biomarker diagnostics  (Predigen Inc)
86
Predigen Inc biomarker diagnostics
Biomarker Diagnostics, supplied by Predigen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biomarker diagnostics/product/Predigen Inc
Average 86 stars, based on 1 article reviews
biomarker diagnostics - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
gene expression analysis  (fluidigm)
97
fluidigm gene expression analysis
Gene Expression Analysis, supplied by fluidigm, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene expression analysis/product/fluidigm
Average 97 stars, based on 1 article reviews
gene expression analysis - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
exploratory biomarkers qc activity  (Evotec Inc)
86
Evotec Inc exploratory biomarkers qc activity
Exploratory Biomarkers Qc Activity, supplied by Evotec Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/exploratory biomarkers qc activity/product/Evotec Inc
Average 86 stars, based on 1 article reviews
exploratory biomarkers qc activity - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
performance human kidney biomarker kit  (R&D Systems)
91
R&D Systems performance human kidney biomarker kit
Performance Human Kidney Biomarker Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/performance human kidney biomarker kit/product/R&D Systems
Average 91 stars, based on 1 article reviews
performance human kidney biomarker kit - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
human magnetic premixed multiplex assay kit  (R&D Systems)
93
R&D Systems human magnetic premixed multiplex assay kit
Human Magnetic Premixed Multiplex Assay Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human magnetic premixed multiplex assay kit/product/R&D Systems
Average 93 stars, based on 1 article reviews
human magnetic premixed multiplex assay kit - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
human biomarker custom premix kit  (R&D Systems)
86
R&D Systems human biomarker custom premix kit
FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each <t>biomarker,</t> adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.
Human Biomarker Custom Premix Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human biomarker custom premix kit/product/R&D Systems
Average 86 stars, based on 1 article reviews
human biomarker custom premix kit - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
human kidney biomarker array kit  (R&D Systems)
92
R&D Systems human kidney biomarker array kit
FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each <t>biomarker,</t> adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.
Human Kidney Biomarker Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human kidney biomarker array kit/product/R&D Systems
Average 92 stars, based on 1 article reviews
human kidney biomarker array kit - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
human tumor  (Exosome Diagnostics)
90
Exosome Diagnostics human tumor
FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each <t>biomarker,</t> adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.
Human Tumor, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human tumor/product/Exosome Diagnostics
Average 90 stars, based on 1 article reviews
human tumor - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
human cytokine premixed kit a  (R&D Systems)
93
R&D Systems human cytokine premixed kit a
FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each <t>biomarker,</t> adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.
Human Cytokine Premixed Kit A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cytokine premixed kit a/product/R&D Systems
Average 93 stars, based on 1 article reviews
human cytokine premixed kit a - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
liquid chromatography  (KCAS Bioanalytical and Biomarker Services)
93
KCAS Bioanalytical and Biomarker Services liquid chromatography
FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each <t>biomarker,</t> adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.
Liquid Chromatography, supplied by KCAS Bioanalytical and Biomarker Services, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liquid chromatography/product/KCAS Bioanalytical and Biomarker Services
Average 93 stars, based on 1 article reviews
liquid chromatography - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each biomarker, adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.

Journal: JAIDS Journal of Acquired Immune Deficiency Syndromes

Article Title: Frailty and Circulating Markers of Inflammation in HIV+ and HIV− Men in the Multicenter AIDS Cohort Study

doi: 10.1097/qai.0000000000001261

Figure Lengend Snippet: FIGURE 2. Relative percentile estimates for the HIV2 frail group, the HIV+ nonfrail group, and the HIV+ frail group (left, middle, and right d, respectively), and 95% confidence limits of the estimates (error bars), for exposure groups relative to the nonfrail HIV2 group, obtained by generalized gamma regression models for each biomarker, adjusted for age, race, study sites, and education, and BMI, current smoking, depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer. Significant differences (P # 0.002) are indicated by #. Marginally significant differences (0.002 , P , 0.05) are those for which the 95% confidence intervals do not include 1.0. Relative percentile estimates are given for differences that were significant or marginally significant. The biomarkers that had $1 significant (P , 0.05) comparison in any analysis are shown.

Article Snippet: Serum levels of soluble (s) CD14, sCD27, sgp130, sIL6 receptor (sIL-6R), sIL-2 receptor-a (sCD25), and sTNF receptor-2 (sTNFR2), plus a cytokine known as B-cellactivating factor or B-lymphocyte stimulator (BAFF/BLyS), and the chemokine CXCL13 (B-lymphocyte chemoattractant/ B-cell-attracting chemokine 1; BLC/BCA1) were measured in one custom-designed multiplexed assay panel (Human Biomarker Custom Premix Kit A, R & D Systems, Minneapolis, MN) per manufacturer’s directions at the University of California, Los Angeles, using a Bio-Plex 200 Luminex instrument and Bio-Plex analysis software (Bio-Rad, Hercules, CA).

Techniques: Biomarker Discovery, Infection, Comparison

FIGURE 3. Relative percentile estimates (d) and 95% confidence limits (error bars) of the estimates for the frail HIV+ men compared with nonfrail HIV+ men. Data were generated using generalized gamma regression models for each biomarker adjusted for age, race, study sites, and education (left bars with d, model 1) and further adjusted for BMI, current smoking, presence of depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer (right bars with d, model 2). Relative percentile differences between the frail and nonfrail HIV+ men that were significantly different at P # 0.002 are indicated by #; those that were significantly different at 0.002 # P #0.05 are those for which the 95% confidence intervals do not include 1.0.

Journal: JAIDS Journal of Acquired Immune Deficiency Syndromes

Article Title: Frailty and Circulating Markers of Inflammation in HIV+ and HIV− Men in the Multicenter AIDS Cohort Study

doi: 10.1097/qai.0000000000001261

Figure Lengend Snippet: FIGURE 3. Relative percentile estimates (d) and 95% confidence limits (error bars) of the estimates for the frail HIV+ men compared with nonfrail HIV+ men. Data were generated using generalized gamma regression models for each biomarker adjusted for age, race, study sites, and education (left bars with d, model 1) and further adjusted for BMI, current smoking, presence of depressive symptoms, HCV infection, hypertension, diabetes, dyslipidemia, kidney disease, liver disease, and cancer (right bars with d, model 2). Relative percentile differences between the frail and nonfrail HIV+ men that were significantly different at P # 0.002 are indicated by #; those that were significantly different at 0.002 # P #0.05 are those for which the 95% confidence intervals do not include 1.0.

Article Snippet: Serum levels of soluble (s) CD14, sCD27, sgp130, sIL6 receptor (sIL-6R), sIL-2 receptor-a (sCD25), and sTNF receptor-2 (sTNFR2), plus a cytokine known as B-cellactivating factor or B-lymphocyte stimulator (BAFF/BLyS), and the chemokine CXCL13 (B-lymphocyte chemoattractant/ B-cell-attracting chemokine 1; BLC/BCA1) were measured in one custom-designed multiplexed assay panel (Human Biomarker Custom Premix Kit A, R & D Systems, Minneapolis, MN) per manufacturer’s directions at the University of California, Los Angeles, using a Bio-Plex 200 Luminex instrument and Bio-Plex analysis software (Bio-Rad, Hercules, CA).

Techniques: Generated, Biomarker Discovery, Infection